Literature DB >> 30056927

Islets Allotransplantation Into Gastric Submucosa in a Patient with Portal Hypertension: 4-year Follow-up.

M Wszola1, A Berman2, A Ostaszewska3, L Gorski3, M Serwanska-Swietek4, J Gozdowska5, K Bednarska2, M Krajewska6, A Lipinska7, A Chmura3, A Kwiatkowski4.   

Abstract

BACKGROUND: Islets transplantation is an established treatment method for patients suffering from brittle diabetes with hypoglycemia unawareness. The standard implantation technique is through the portal vein into the liver. In case of liver diseases or portal hypertension, finding an extra-hepatic site is recommended. There have been attempts to perform islets transplantations into muscles and into the gastric submucosa.
OBJECTIVE: The aim of this study is to show a 4-year follow-up of allotransplantation into gastric submucosa in a case of portal hypertension observed during the procedure of islets infusion. PATIENTS AND METHODS: A 36-year-old woman with complicated diabetes for over 30 years was selected to receive simultaneous islets and kidney transplantation. The patient underwent an unsuccessful simultaneous pancreas and kidney transplantation 2 years earlier in another transplantation center. The patient's daily insulin requirement was 60 IU, which corresponded to 1.15 IU/kg of body weight. The HbA1c level was 7.4%. C-peptide levels, both fasting and stimulated, were 0.01 ng/mL. On December 7, 2013, the patient received transplanted kidney and islets procured from the same donor. Only 124,000 islets equivalents (IEQ) were isolated (2400 IEQ/kg body weight). Islets were suspended in 300 mL of Ringer's solution along with albumin, antibiotics, and heparin. After infusing 100 mL of the islets suspension into the portal vein, pressure in portal vein increased from 5 mm Hg to 23 mm Hg. Despite stopping the infusion, pressure did not drop after 30 minutes. The decision was made to transplant the reminder of the islets (200 mL) into the gastric wall.
RESULTS: No complications were observed after the procedure. Serum creatinine level was 1.6 mg/dL on day 10 and 1.5 mg/dL 4 years after the transplantation. Fasting C-peptide levels were 1.7, 0.65, 0.55, 0.69, 0.68, and 0.2 ng/mL at 1, 3, 6, 12, 18, and 36 months after the transplantation, respectively. HbA1c levels were 5.2, 6.4, 4.7, 5.2, and 5.9% at 3, 6, 12, 18, and 36 months, respectively. The patient's insulin requirement dropped to 15 U/day immediately after transplantation and equaled 20 and 27 U/day at 18 and 48 months after the simultaneous islet and kidney transplantation, respectively.
CONCLUSION: Allotransplantation of islets into the gastric wall may be a safe alternative in cases of contraindications for transplantation into the portal vein.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30056927     DOI: 10.1016/j.transproceed.2018.02.170

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

Review 1.  Considerations for an Alternative Site of Islet Cell Transplantation.

Authors:  Poppy Addison; Karina Fatakhova; Horacio L Rodriguez Rilo
Journal:  J Diabetes Sci Technol       Date:  2019-08-09

2.  Bionic Organs: Shear Forces Reduce Pancreatic Islet and Mammalian Cell Viability during the Process of 3D Bioprinting.

Authors:  Marta Klak; Patrycja Kowalska; Tomasz Dobrzański; Grzegorz Tymicki; Piotr Cywoniuk; Magdalena Gomółka; Katarzyna Kosowska; Tomasz Bryniarski; Andrzej Berman; Agnieszka Dobrzyń; Wojciech Sadowski; Bartosz Górecki; Michał Wszoła
Journal:  Micromachines (Basel)       Date:  2021-03-14       Impact factor: 2.891

3.  A Worldwide Survey of Activities and Practices in Clinical Islet of Langerhans Transplantation.

Authors:  Thierry Berney; Axel Andres; Melena D Bellin; Eelco J P de Koning; Paul R V Johnson; Thomas W H Kay; Torbjörn Lundgren; Michael R Rickels; Hanne Scholz; Peter G Stock; Steve White
Journal:  Transpl Int       Date:  2022-08-11       Impact factor: 3.842

4.  Islet Transplantation - perspective from Poland.

Authors:  A Dębska-Ślizień; M Wszoła; P Bachul; J Gulczyński; I Żygowska; A Berman; J Gołębiewska; M Komorniczak; P Witkowski
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2019-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.